Quick Answer
Gain Therapeutics, Inc. reported Research And Development Expense of $10.21 million for the year ending 2025.
- Gain Therapeutics, Inc. showed a decrease of -5.4% in Research And Development Expense from 2024 to 2025.
- This data is from Gain Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $417.3 thousand | Q2 2020: $438.9 thousand | Q3 2020: $427.5 thousand | Q1 2021: $1.42 million | Q2 2021: $1.79 million | Q3 2021: $2.48 million | Q1 2022: $1.56 million | Q2 2022: $2.58 million | Q3 2022: $1.96 million | Q1 2023: $2.79 million | Q2 2023: $3.99 million | Q3 2023: $2.37 million | Q1 2024: $2.51 million | Q2 2024: $4.44 million | Q3 2024: $2.62 million | Q1 2025: $2.26 million | Q2 2025: $2.76 million | Q3 2025: $2.85 million.
- Over the full 6 years of available data (2020 to 2025), Gain Therapeutics, Inc.'s Research And Development Expense has grown by 352.1%.
- Historical annual values: Fiscal year 2025: $10.21 million | Fiscal year 2024: $10.79 million | Fiscal year 2023: $11.52 million | Fiscal year 2022: $8.38 million | Fiscal year 2021: $7.16 million | Fiscal year 2020: $2.26 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: